Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of CPL500036 for levodopa-induced dyskinesia in Parkinson's disease
2020-006004-16Phase 2Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cpl500036 in levodopa-induced dyskinesia (LID) (3 arms), sponsored by Celon Pharma S.A. Primary endpoint: Change from baseline in total UDysRS score at Week 4. Started Apr 2021; status: completed.
02
Drugs
cpl500036
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on 2020-006004-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006004-16.